High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden

References

• James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–8.
   PubMed Web of Science ®Google Scholar
• Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652–1660.
   PubMed Web of Science ®Google Scholar
• Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274–4281.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of thetyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine 2005; 352: 1779–1790.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J et al. Activating mutation in thetyrosine kinase JAK2 in polycythemia vera, essential thrombo-cythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Green AR. The myeloproliferative disorders. New England Journal of Medicine 2006; 355: 2452–2466.
   PubMed Web of Science ®Google Scholar
• Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006; 108: 2435–2437.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, GuglielmelliP. A quantitative assay for JAK2(V617F) mutation in myelopro-liferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 2006; 20: 1055–1060.
   PubMed Web of Science ®Google Scholar
• Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis - impact on disease phenotype. European Journal of Haematology 2007; 79: 508–515.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythe-mia vera or essential thrombocythemia. Blood 2007; 110: 840–846.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Strand .J.J, Lasho TL et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007; 21, 2074–2075.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Scott LM, Buck G et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Pancrazzi A et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–1849.
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Lasho TL, Schwager SM et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. British Journal of Haematology 2005; 131: 208–213.
   PubMed Web of Science ®Google Scholar
• Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombo-cythaemia. British Journal of Haematology 2006; 132: 244–245.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Baxter EJ, Beer PA et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations and role in leukemic transformation. Blood 2006; 108: 3548–3555.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007; 92: 135–136.
   PubMed Web of Science ®Google Scholar
• Heller PG, Lev PR, Salim JP et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. European Journal of Haematology 2006; 77: 210–216.
   PubMed Web of Science ®Google Scholar
• Kittur J, Knudson RA, Lasho TL AP et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007; 109: 2279–2284.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia 2007; 21: 2210–2212.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Guerini V et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109: 2310–2313.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Annals of Hematology 2003; 82: 148–152.
   PubMed Web of Science ®Google Scholar
• Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2V617F mutation involves B- and T-lymphocyte lineages in a sub-group of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. British Journal of Haematology 2007;136: 745–751.
   PubMed Web of Science ®Google Scholar
• Jones AV, Kreil S, Zoi K et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2468.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Seminars in Thrombosis and Hemostasis 2007; 33: 313–320.
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proceedings 2006; 81: 159–166.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Schwager S et al. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder. Leukemia 2007; 21: 1828–1829.
   PubMed Web of Science ®Google Scholar
• Bellosillo B, Martinez-Aviles L, Gimeno E et al. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. Leukemia 2007; 21: 1331–1332.
   PubMed Web of Science ®Google Scholar
• Toyama K, Karasawa M, Yamane A et al. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. British Journal of Haematology 2007; 139: 64–69.
   PubMed Web of Science ®Google Scholar